Walking impairment in patients with multiple sclerosis – a new therapeutic approach and clinical potential of dalfampridine extended release tablets

References

• National Multiple Sclerosis SocietyFAQs about MS [webpage on the Internet]New YorkNational Multiple Sclerosis Society nd. Available from: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/faqs-about-ms/index.aspxAccessed January 11, 2012
   Google Scholar
• Whetten-GoldsteinKSloanFAGoldsteinLBKulasEDA comprehensive assessment of the cost of multiple sclerosis in the United StatesMult Scler1998454194259839302
   PubMed Web of Science ®Google Scholar
• KobeltGBergJAtherlyDHadjimichaelOCosts and quality of life in multiple sclerosis. A cross-sectional study in the United StatesNeurology2006661696170216769943
   PubMed Web of Science ®Google Scholar
• KobeltGBergJLindgrenPFredriksonSJonssonBCosts and quality of life of patients with multiple sclerosis in EuropeJ Neurol Neurosurg Psychiatry20067791892616690691
   PubMed Web of Science ®Google Scholar
• SalterARCutterGRTyryTMarrieRAVollmerTImpact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MSCurr Med Res Opin201026249350020014979
   PubMed Web of Science ®Google Scholar
• FigvedNMyhrKMLarsenJPAarslandDCaregiver burden in multiple sclerosis: the impact of neuropsychiatric symptomsJ Neurol Neurosurg Psychiatry200778101097110217237144
   PubMed Web of Science ®Google Scholar
• DunnJImpact of mobility impairment on the burden of caregiving in individuals with multiple sclerosisExpert Rev Pharmacoecon Outcomes Res201010443344020482233
   PubMed Web of Science ®Google Scholar
• BuchananRHuangCHealth-related quality of life among informal caregivers assisting people with multiple sclerosisDisabil Rehabil201133211312120450245
   PubMed Web of Science ®Google Scholar
• WaxmanSGDemyelinating diseases – new pathological insights, new therapeutic targets [editorial]N Engl J Med199833853233259445415
   PubMed Web of Science ®Google Scholar
• SmithKJMcDonaldWIThe pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the diseasePhilos Trans R Soc Lond B Biol Sci199935413901649167310603618
   PubMed Web of Science ®Google Scholar
• DuttaRTrappBDPathogenesis of axonal and neuronal damage in multiple sclerosisNeurology20076822 Suppl 3S22S3117548565
   PubMed Web of Science ®Google Scholar
• McDonaldWIPathophysiology in multiple sclerosisBrain19749711791964373118
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology19833311144414526685237
   PubMed Web of Science ®Google Scholar
• RudickRACutterGBaierMUse of the multiple sclerosis functional composite to predict disability in relapsing MSNeurology2001561324133011376182
   PubMed Web of Science ®Google Scholar
• SutliffMContribution of impaired mobility to patient burden in multiple sclerosisCurr Med Res Opin201026110911919916707
   PubMed Web of Science ®Google Scholar
• YildizMSlower walking speed limits the activities of daily living of multiple sclerosis patients [abstract]J Neurol20112589620803027
   PubMed Web of Science ®Google Scholar
• LaRoccaNImpact of walking impairment in multiple sclerosis: perspectives of patients and care partnersPatient20114318920121766914
   PubMedGoogle Scholar
• HeesenCBohmJReichCKasperJGoebelMGoldSMPatient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuableMult Scler200814798899118505775
   PubMed Web of Science ®Google Scholar
• MyhrKMRiiseTVedelerCNortvedtMWGrønningRNylandHIDisability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pensionMult Scler200171596511321195
   PubMed Web of Science ®Google Scholar
• MartinCLPhillipsBAKilpatrickTJGait and balance impairment in early multiple sclerosis in the absence of clinical disabilityMult Scler200612562062817086909
   PubMed Web of Science ®Google Scholar
• GoldmanMAnn MarrieRCohenJAEvaluation of the six-minute walk in multiple sclerosis subjects and healthy controlsMult Scler20081438339017942508
   PubMed Web of Science ®Google Scholar
• van AschPImpact of mobility impairment in multiple sclerosis 2 – patients’ perspectivesEuropean Neurological Review201162115120
   Google Scholar
• Ben-ZachariaABTherapeutics for multiple sclerosis symptomsMt Sinai J Med201178217619121425263
   PubMedGoogle Scholar
• de SaJCAirasLBartholomeESymptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practiceTher Adv Neurol Disord20114313916821694816
   PubMedGoogle Scholar
• FrohmanTCCastroWShahASymptomatic therapy in multiple sclerosisTher Adv Neurol Disord201142839821694806
   PubMedGoogle Scholar
• SamkoffLMGoodmanADSymptomatic management in multiple sclerosisNeurol Clin201129244946321439453
   PubMed Web of Science ®Google Scholar
• Ampyra^® (dalfampridine) extended release tablets [prescribing information]New YorkAcorda Therapeutics, Inc2010
   Google Scholar
• Therapeutic Goods Administration, Department of Health and Aging, Australian GovernmentAustralian Public Assessment Report for FampridineWodenTherapeutic Goods Administration2011 Available from: http://www.tga.gov.au/pdf/auspar/auspar-fampyra.pdfAccessed January 11, 2012
   Google Scholar
• European Medicines Agency Committee for Medicinal Products for Human UseSummary of Opinion (Initial Authorisation): Fampyra; FampridineLondonEuropean Medicines Agency2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002097/WC500106531.pdfAccessed January 11, 2012
   Google Scholar
• DunnJBlightADalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosisCurr Med Res Opin20112771415142321595605
   PubMed Web of Science ®Google Scholar
• TargEFKocsisJD4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerveBrain Res198532823583612985185
   PubMed Web of Science ®Google Scholar
• ShiRBlightARDifferential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cordNeuroscience19977725535629472411
   PubMed Web of Science ®Google Scholar
• StefoskiDDavisFAFautMSchaufCL4-Aminopyridine improves clinical signs in multiple sclerosisAnn Neurol198721171772435223
   PubMed Web of Science ®Google Scholar
• DavisFAStefoskiDRushJOrally administered 4-aminopyridine improves clinical signs in multiple sclerosisAnn Neurol19902721861922317014
   PubMed Web of Science ®Google Scholar
• Van DiemenHAPolmanCHvan DongenTMThe effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over studyAnn Neurol19923221231301510353
   PubMed Web of Science ®Google Scholar
• SchwidSRPetrieMDMcDermottMPTierneyDSMasonDHG oodmanADQuantitative assessment of sustained-release 4- aminopyridine for symptomatic treatment of multiple sclerosisNeurology19974848178219109861
   PubMed Web of Science ®Google Scholar
• BlightARHenneyHRIIIPharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteersClin Ther200931232833519302905
   PubMed Web of Science ®Google Scholar
• Van DiemenHAPolmanCHKoetsierJCvan LoenenACNautaJJBertelsmannFW4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safetyClin Neuropharmacol19931631952048504436
   PubMed Web of Science ®Google Scholar
• BeverCTJrYoungDAndersonPAThe effects of 4- aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trialNeurology1994446105410598208399
   PubMed Web of Science ®Google Scholar
• HayesKCKatzMADevaneJGPharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injuryJ Clin Pharmacol200343437938512723458
   PubMed Web of Science ®Google Scholar
• SmithWSwanSMarburyTHenneyHRIIISingle-dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairmentJ Clin Pharmacol201050215115919966074
   PubMed Web of Science ®Google Scholar
• VollmerTHenneyHRIIIPharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I-II, open-label trialClin Ther200931102206221419922891
   PubMed Web of Science ®Google Scholar
• MarchBCardiTAssessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individualsExpert Opin Investig Drugs2009181218071815
   PubMed Web of Science ®Google Scholar
• HenneyHRIIIBlightAFaustBEffect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteersAm J Health Syst Pharm2011682148215422058101
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• SainiSDSchoenfeldPKaulbackKDubinskyMCEffect of medication dosing frequency on adherence in chronic diseasesAm J Manag Care2009156e22e3319514806
   PubMed Web of Science ®Google Scholar
• RichterAAntonSEKochPDennettSLThe impact of reducing dose frequency on health outcomesClin Ther20032582307233514512137
   PubMed Web of Science ®Google Scholar
• GoodmanADBrownTRKruppLSustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialLancet2009373966573273819249634
   PubMed Web of Science ®Google Scholar
• GoodmanADBrownTREdwardsKRA phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnn Neurol201068449450220976768
   PubMed Web of Science ®Google Scholar
• RudickRACutterGReingoldSThe multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis clinical trialsMult Scler2002835936512356200
   PubMed Web of Science ®Google Scholar
• HobartJCRiaziALampingDLFitzpatrickRThompsonAJMeasuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)Neurology2003601313612525714
   PubMed Web of Science ®Google Scholar
• BethouxFABennettSEEvaluating walking mobility in patients with multiple sclerosis: utility of instruments in clinical trials and clinical practiceInt J MS Care201113141424453700
   PubMedGoogle Scholar
• CréangeASerreILevasseurMWalking capacities in multiple sclerosis measured by global positioning system odometerMult Scler200713222022317439888
   PubMed Web of Science ®Google Scholar
• CutterGRBaierMLRudickRADevelopment of a multiple sclerosis functional composite as a clinical trial outcome measureBrain1999122Pt 587188210355672
   PubMed Web of Science ®Google Scholar
• CohenJAFischerJSBolibrushDMIntrarater and interrater reliability of the MS functional composite outcome measureNeurology200054480280610690966
   PubMed Web of Science ®Google Scholar
• KalkersNFde GrootVLazeronRHMS functional composite: relation to disease phenotype and disability strataNeurology20005461233123910746590
   PubMed Web of Science ®Google Scholar
• FischerJSRudickRACutterGRReingoldSCThe Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task ForceMult Scler19995424425010467383
   PubMed Web of Science ®Google Scholar
• KaufmanMMoyerDNortonJThe significant change for the timed 25-foot walk in the multiple sclerosis functional compositeMult Scler2000628629010962550
   PubMed Web of Science ®Google Scholar
• HoogervorstELKalkersNFCutterGRUitdehaagBMPolmanCHThe patient’s perception of a (reliable) change in the multiple sclerosis functional compositeMult Scler200410556014760953
   PubMed Web of Science ®Google Scholar
• GijbelsDDalgasURombergAWhich walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core setMult Scler201118336437121952098
   PubMed Web of Science ®Google Scholar
• GoodmanADBrownTRCohenJADose-comparison trial of sustained-release fampridine in multiple sclerosisNeurology200871151134114118672472
   PubMed Web of Science ®Google Scholar
• SchwidSRPetrieMDMcDermottMPTierneyDSMasonDHGoodmanADQuantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosisNeurology19974848178219109861
   PubMed Web of Science ®Google Scholar
• SchwidSRGoodmanADMcDermottMPBeverCFCookSDQuantitative functional measures in MS: what is a reliable change?Neurology20025881294129611971105
   PubMed Web of Science ®Google Scholar
• KragtJJvan der LindenFANielsenJMUitdehaagBMPolmanCHClinical impact of 20% worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosisMult Scler200612559459817086905
   PubMed Web of Science ®Google Scholar
• EdwardsKBrownTSchapiroRDalfampridine extended release tablets improve walking speed across a wide range of baseline deficits: pooled data from three placebo-controlled studies in patients with multiple sclerosis [abstract]Neurology201074Suppl 2A565
   Google Scholar
• BrownTSchapiroREdwardsKResponse to treatment with dalfampridine extended release tablets in patients with multiple sclerosis is independent of baseline patient characteristics and concomitant immunomodulator therapy [abstract]Neurology201074Suppl 2A543
   Google Scholar
• Goodman A, on behalf of the MS-F203, MS-F204, and extension study investigatorsUpdated analysis of open-label extension studies of dalfampridine extended release tablets in multiple sclerosis [abstract]Mult Scler201117SupplS245S246
   Google Scholar
• CadavidDTangYO’NeillGResponsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosisRev Neurol201051632132920839168
   PubMed Web of Science ®Google Scholar
• HobartJProlonged-release fampridine for multiple sclerosis: was the effect on walking ability clinically significant? [abstract]Mult Scler201016SupplS72
   Google Scholar
• DworkinRHTurkDCWyrwichKWInterpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendationsJ Pain20089210512118055266
   PubMed Web of Science ®Google Scholar
• HobartJResponder or non-responder, that is the question. Was the responder definition used in the dalfampridine extended release studies clinically meaningful? [abstract]Neurology201176Suppl 4A70
   Google Scholar
• JaraMHenneyHRIIIWesselTBarkerGKargmanDDalfampridine extended-release tablets: one year of post-marketing safety experience in the United States [abstract]Mult Scler201117Suppl 10S216
   Google Scholar
• NicolettiASofiaVBiondiREpilepsy and multiple sclerosis in Sicily: a population-based studyEpilepsia200344111445144814636354
   PubMed Web of Science ®Google Scholar
• PoserCMBrinarVVEpilepsy and multiple sclerosisEpilepsy Behav20034161212609222
   PubMed Web of Science ®Google Scholar
• ErikssonMBen-MenachemEAndersenOEpileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosisMult Scler20028649549912474990
   PubMed Web of Science ®Google Scholar